- Medicine
Pathogenic activating mutations in PIK3CA or NRAS were the most common genetic findings in a lymphatic malformation patient cohort and an N-of-1 trial of the PI3Kα inhibitor alpelisib in a patient with a PIK3CA mutation confirmed these findings are actionable.